Hepatitis B and C surveillance and screening programmes in the non-EU/EEA Member States of the WHO European Region: survey findings from 10 countries, 2012

A Mozalevskis¹, I Eramova¹, K Safreed-Harmon², JV Lazarus²

1. World Health Organization (WHO) Regional Office for Europe, Copenhagen, Denmark
2. CHIP, Centre for Health and Infectious Disease Research and WHO Collaborating Centre on HIV and Viral Hepatitis, Rigshospitalet, University of Copenhagen, Denmark

Correspondence: Jeffrey V. Lazarus (Jeffrey.Lazarus@regionh.dk)

Citation style for this article:

Introduction

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections can result in acute and chronic hepatitis and are major public health problems in many parts of the world. Together they are thought to cause more than 1.4 million deaths per year worldwide, mostly due to chronic hepatitis sequelae such as liver cirrhosis and liver cancer [1]. In the World Health Organization (WHO) European Region, an estimated 1.8 per cent of adults are chronically infected with hepatitis B; moreover hepatitis C RNA (HCV RNA) prevalence is estimated to be 2.0 per cent. The eastern part of the Region is disproportionately affected, whereby two-thirds of those infected with HBV or HCV live outside of the European Union (EU) and European Free Trade Association [2]. Throughout the Region, there is evidence of high levels of HCV infection and to a lesser extent HBV infection in populations of people who inject drugs (PWID) [3]. Other notable transmission pathways for hepatitis B in Europe include sexual intercourse, both heterosexual and among men who have sex with men (MSM), and nosocomial transmission in some countries. Available epidemiological evidence on HBV and HCV in migrant populations suggests that in several European countries, many migrant groups are disproportionately affected [4,5]. However, precise data on disease burden and changing trends are lacking in most countries [6], and information on existing viral hepatitis surveillance systems and screening practices is not available at the regional level.

WHO defines public health surveillance as ‘the continuous, systematic collection, analysis and interpretation of health-related data needed for the planning, implementation, and evaluation of public health practice’ [7]. Surveillance of diseases and health conditions is important for guiding decision-making about how health systems should be configured at the subnational, national, regional and global levels. A key principle of surveillance is that the surveillance system should be designed to address the specific public health objectives at hand [8]. In the case of HBV and HCV, this principle suggests a need for surveillance systems that are designed to address the specific public health objectives at hand [8].
Table 1: Respondent and non-respondent countries to a survey on hepatitis B and C surveillance and screening programmes, 2012

<table>
<thead>
<tr>
<th>Responded to survey (n=10)</th>
<th>Did not respond to survey (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Armenia; Azerbaijan; Belarus; Croatia; Kyrgyzstan; Moldova; Montenegro; Russia; Tajikistan; Ukraine</td>
<td>Albania; Bosnia and Herzegovina; Bulgaria; Kazakhstan; Serbia; the former Yugoslav Republic of Macedonia; Turkey; Uzbekistan</td>
</tr>
</tbody>
</table>

systems with the capacity to capture and synthesise a complex array of data on disease transmission and progression. This is difficult, since both diseases manifest in ways that can make it highly challenging to track incidence, prevalence, morbidity, mortality and the impact of prevention and treatment interventions [9,10].

In 2006, the European Parliament directed the European Centre for Disease Prevention and Control (ECDC) to prioritise the harmonisation of viral hepatitis surveillance in the EU [11]. In the course of this work, ECDC conducted a survey in 2009 to gather information about various features of national surveillance systems in the EU and European Economic Area (EEA) such as the types of surveillance conducted and the types of data collected [12]. Information of this nature is valuable for interpreting surveillance findings and for assessing how surveillance systems can be further strengthened and harmonised. No comparable studies have been conducted to assess the characteristics of viral hepatitis surveillance systems and screening programmes in European countries outside of the EU/EEA.

The following paper presents findings from a survey conducted by the WHO Regional Office for Europe among mostly non-EU/EEA Member States in Central and Eastern Europe, including Central Asia.

Methods

In 2012, the WHO Regional Office for Europe conducted a survey on viral hepatitis surveillance in 17 non-EU/EEA Member States comprising Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina*, Croatia, Kazakhstan, Kyrgyzstan, Moldova, Montenegro, Russia, Serbia, Tajikistan, the former Yugoslav Republic of Macedonia, Turkey, Ukraine and Uzbekistan. In addition, Bulgaria was included. These countries were selected because little is known about their current practices. In each country, the person recognised by WHO via the respective ministry of health as the governmental focal point for viral hepatitis surveillance was asked to complete the survey.

The survey consisted of 20 questions relating to HBV and HCV surveillance systems, case definitions and populations screened for hepatitis. Respondents also had the option of providing comments. The survey was developed in English by one of this paper’s co-authors who, as a native Russian speaker, ensured correct translation of the questionnaire into Russian. English- and Russian-language versions of the survey were distributed via email to the country focal points. Data collection took place between 1 July and 31 August 2012 and there was one reminder sent midway through the data collection period to increase the response rate.

For the purpose of this study, and with a secondary aim of comparing the findings from non-EU/EEA countries with the findings from the 2009 ECDC survey [12], we selected 10 of the questions, which covered objectives and main features of viral hepatitis surveillance systems; types of data collected through viral hepatitis case reporting; and data linkages with the associated conditions and populations screened for HBV and HCV. For nine of the questions (which are further detailed in a table within the result section), respondents were instructed to tick check-boxes to indicate their answers. The tenth question asked ‘Which of the following populations, if any, are screened for hepatitis?’ and was followed by check-boxes for 18 options identified. These options and responses are also further detailed in a separate table in the results. One of these options was ‘Other groups – please specify’, and space was provided for respondents to report this information. Simple definitions of terms such as ‘population-based surveillance’ and ‘active surveillance’ were incorporated into survey questions. All survey responses were entered into Microsoft Excel and a descriptive analysis was performed.

Results

Respondents

Completed surveys were received from focal points in 10 of 18 countries as described in Table 1. During the time of this study, all respondent countries were WHO European Region Member States, which were not part of the EU/EEA.

Surveillance objectives

All 10 survey respondents indicated that the objectives of HBV and HCV surveillance systems included monitoring trends and detecting outbreaks. Most stated that the goals were also to monitor changes in disease distribution (n=9 countries) and identify at-risk populations (n=8 for HBV; n=7 for HCV) (Table 2). Fewer respondents reported planning and evaluating control measures (n=7 for HBV; n=6 for HCV), identifying research needs (n=3 for both diseases) and improving epidemiological knowledge as specific surveillance objectives (n=6).
### Table 2A
Hepatitis surveillance system features of 10 non-European Union/European Economic Area Member States of the World Health Organization European Region, 2012

<table>
<thead>
<tr>
<th>Characteristics of the surveillance system</th>
<th>HBV</th>
<th>HCV</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of countries responding</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>(names of respondent countries)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What are the objectives of the surveillance system?</td>
<td>10 (Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Moldova, Montenegro, Russia, Tajikistan, Ukraine)</td>
<td>10 (Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Moldova, Montenegro, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Monitor trends</td>
<td>10 (Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Moldova, Montenegro, Russia, Tajikistan, Ukraine)</td>
<td>10 (Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Moldova, Montenegro, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Detect outbreaks</td>
<td>10 (Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Moldova, Montenegro, Russia, Tajikistan, Ukraine)</td>
<td>9 (Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Moldova, Montenegro, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Monitor changes in disease distribution</td>
<td>9 (Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Moldova, Montenegro, Russia, Tajikistan, Ukraine)</td>
<td>9 (Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Moldova, Montenegro, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Plan and evaluate control measures</td>
<td>7 (Armenia, Kyrgyzstan, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
<td>6 (Armenia, Kyrgyzstan, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Identify research needs and facilitate research</td>
<td>3 (Armenia, Montenegro, Moldova)</td>
<td>3 (Armenia, Montenegro, Moldova)</td>
</tr>
<tr>
<td>Improve knowledge of epidemiology</td>
<td>6 (Armenia, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
<td>(Armenia, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Identify at-risk populations</td>
<td>8 (Armenia, Azerbaijan, Belarus, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
<td>7 (Armenia, Belarus, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Other (please comment)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>In your country, what is the legal basis of hepatitis reporting?</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Mandatory*</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Voluntary*</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Would you describe your surveillance system as active or passive?</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Active – the proactive searching for case reports from the population</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Passive – the passive receiving of case reports from surveillance structures within the population</td>
<td>9 (Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
<td>9 (Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Depends on type of surveillance</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Which of the following surveillance methods are used?</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Population-based (all cases reported)</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Risk group-based (occupational or behavioural risk group monitoring)</td>
<td>7 (Armenia, Belarus, Croatia, Moldova, Russia, Tajikistan, Ukraine)</td>
<td>6 (Armenia, Belarus, Croatia, Moldova, Russia, Tajikistan)</td>
</tr>
<tr>
<td>Sentinel (all cases from selected reporting sites)</td>
<td>0</td>
<td>1 (Tajikistan)</td>
</tr>
<tr>
<td>Other (surveys, anonymous sampling, etc.)</td>
<td>3 (Croatia, Russia, Ukraine)</td>
<td>3 (Croatia, Russia, Ukraine)</td>
</tr>
<tr>
<td>What types of cases are included in surveillance?</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Acute*</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Chronic*</td>
<td>8 (Belarus, Croatia, Kyrgyzstan, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
<td>8 (Belarus, Croatia, Kyrgyzstan, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>2 (Belarus, Croatia, Russia)</td>
<td>(Croatia, Russia)</td>
</tr>
<tr>
<td>Suspected*</td>
<td>3 (Armenia, Croatia, Russia)</td>
<td>3 (Armenia, Croatia, Russia)</td>
</tr>
<tr>
<td>Hepatitis (undefined*)</td>
<td>5 (Azerbaijan, Belarus, Croatia, Montenegro, Ukraine)</td>
<td>5 (Azerbaijan, Belarus, Croatia, Montenegro, Ukraine)</td>
</tr>
<tr>
<td>Other (please comment)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus.

* This term was not defined and its interpretation was at the discretion of the survey respondent.
**Table 2b**
Hepatitis surveillance system features of 10 non-European Union/European Economic Area Member States of the World Health Organization European Region, 2012

<table>
<thead>
<tr>
<th>Characteristics of the surveillance system</th>
<th>HBV Number of countries responding (names of respondent countries)</th>
<th>HCV Number of countries responding (names of respondent countries)</th>
</tr>
</thead>
<tbody>
<tr>
<td>What case classifications are included in surveillance?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Probable*</td>
<td>(Armenia, Croatia, Russia)</td>
<td>(Armenia, Croatia, Russia)</td>
</tr>
<tr>
<td>Confirmed*</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Montenegro, Russia, Tajikistan, Ukraine)</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Montenegro, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Epidemiologically linked</td>
<td>(Azerbaijan, Belarus, Moldova, Russia)</td>
<td>(Azerbaijan, Belarus, Moldova, Russia)</td>
</tr>
<tr>
<td>Other classification (please comment)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Which of the following demographic data are collected (if any)?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient identifier, address, sex, occupation, birth date, place of birth</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Pregnancy status</td>
<td>(Armenia, Azerbaijan, Moldova, Russia, Tajikistan)</td>
<td>(Armenia, Azerbaijan, Moldova, Russia, Tajikistan)</td>
</tr>
<tr>
<td>Ethnic group</td>
<td>2 (Armenia, Moldova)</td>
<td>2 (Armenia, Moldova)</td>
</tr>
<tr>
<td>Country in which infection was acquired</td>
<td>(Armenia, Azerbaijan, Moldova, Russia)</td>
<td>(Armenia, Azerbaijan, Moldova, Russia)</td>
</tr>
<tr>
<td>Date of onset</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Montenegro, Moldova, Russia, Ukraine)</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Montenegro, Moldova, Russia, Ukraine)</td>
</tr>
<tr>
<td>Date of diagnosis</td>
<td>(Armenia, Azerbaijan, Belarus, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
<td>(Armenia, Azerbaijan, Belarus, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Date of reporting</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Montenegro, Moldova, Russia, Tajikistan)</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Montenegro, Moldova, Russia, Tajikistan)</td>
</tr>
<tr>
<td>Which of the following classification data are collected from cases?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical symptoms</td>
<td>6 (Armenia, Azerbaijan, Belarus, Moldova, Russia, Ukraine)</td>
<td>6 (Armenia, Azerbaijan, Belarus, Moldova, Russia, Ukraine)</td>
</tr>
<tr>
<td>Laboratory results</td>
<td>(Armenia, Azerbaijan, Belarus, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
<td>(Armenia, Azerbaijan, Belarus, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Epidemiological information*</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>For which of the following associated conditions is case data linked to/collection?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver transplant</td>
<td>3 (Armenia, Belarus, Moldova)</td>
<td>3 (Armenia, Belarus, Moldova)</td>
</tr>
<tr>
<td>Liver cancer</td>
<td>(Armenia, Kyrgyzstan, Moldova, Tajikistan)</td>
<td>(Armenia, Kyrgyzstan, Moldova, Tajikistan)</td>
</tr>
<tr>
<td>HBV or HCV coinfection</td>
<td>(Armenia, Azerbaijan, Belarus, Kyrgyzstan, Moldova, Tajikistan)</td>
<td>(Armenia, Azerbaijan, Belarus, Kyrgyzstan, Moldova, Tajikistan)</td>
</tr>
<tr>
<td>HIV coinfection</td>
<td>(Armenia, Azerbaijan, Belarus, Kyrgyzstan, Moldova, Tajikistan)</td>
<td>(Armenia, Azerbaijan, Belarus, Kyrgyzstan, Moldova, Tajikistan)</td>
</tr>
<tr>
<td>Hepatitis-associated mortality</td>
<td>5 (Armenia, Belarus, Kyrgyzstan, Moldova, Tajikistan)</td>
<td>5 (Armenia, Belarus, Kyrgyzstan, Moldova, Tajikistan)</td>
</tr>
</tbody>
</table>

HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus.

* This term was not defined and its interpretation was at the discretion of the survey respondent.
Surveillance system characteristics

All 10 countries reported that their surveillance systems for HBV and HCV were mandatory rather than voluntary, and nine characterised the surveillance systems as passive rather than active (Table 2). Surveillance systems in all 10 countries reportedly employed population-based methods, and in several countries there was risk group-based surveillance as well (n = 7 for HBV and n = 6 for HCV). The only country that reported carrying out sentinel surveillance was Tajikistan (for hepatitis C but not hepatitis B). All countries reported including acute HBV and HCV cases in surveillance, and all but two countries (Armenia and Azerbaijan) reported including chronic cases as well. Five respondents indicated that ‘undefined’ hepatitis cases were included in surveillance. Nine countries reported including ‘confirmed’ cases in surveillance, and three of those countries (Armenia, Croatia and Russia) also included ‘probable’ cases.

### Table 3

<table>
<thead>
<tr>
<th>Population</th>
<th>HBV Number of countries responding (names of respondent countries)</th>
<th>HCV Number of countries responding (names of respondent countries)</th>
</tr>
</thead>
<tbody>
<tr>
<td>People who inject drugs</td>
<td>(Belarus, Croatia, Moldova, Russia, Ukraine)</td>
<td>(Belarus, Croatia, Moldova, Russia, Ukraine)</td>
</tr>
<tr>
<td>Contacts of infected people who inject drugs</td>
<td>(Belarus, Croatia)</td>
<td>(Belarus, Croatia)</td>
</tr>
<tr>
<td>Sex workers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men who have sex with men</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inmates in closed settings</td>
<td>(Croatia, Russia)</td>
<td>(Croatia, Russia)</td>
</tr>
<tr>
<td>People living with HIV</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Montenegro, Moldova, Russia)</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Montenegro, Moldova, Russia, Tajikistan)</td>
</tr>
<tr>
<td>Transfusion/organ transplant recipients</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Moldova, Russia, Ukraine)</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Moldova, Russia, Ukraine)</td>
</tr>
<tr>
<td>HBV- or HCV-infected patients</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Montenegro, Moldova, Russia, Ukraine)</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Montenegro, Moldova, Russia, Ukraine)</td>
</tr>
<tr>
<td>Persons born in endemic areas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood and organ donors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalised patients/pre-operative patients</td>
<td>(Armenia, Kyrgyzstan, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
<td>(Armenia, Kyrgyzstan, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
</tr>
<tr>
<td>Persons who require immunosuppressive therapy</td>
<td>(Armenia, Croatia, Moldova)</td>
<td>(Armenia, Croatia, Moldova)</td>
</tr>
<tr>
<td>Pregnant women</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Kyrgyzstan, Montenegro, Moldova, Russia, Ukraine)</td>
<td>(Azerbaijan, Belarus, Kyrgyzstan, Montenegro, Moldova, Russia)</td>
</tr>
<tr>
<td>Family members</td>
<td>(Armenia, Belarus, Croatia, Kyrgyzstan, Montenegro, Moldova, Russia, Ukraine)</td>
<td>(Armenia, Belarus, Kyrgyzstan, Montenegro, Moldova, Russia)</td>
</tr>
<tr>
<td>Sexual contacts of infected persons</td>
<td>(Armenia, Croatia, Moldova)</td>
<td>(Armenia, Croatia, Moldova)</td>
</tr>
<tr>
<td>Haemodialysis patients</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Montenegro, Moldova, Russia, Tajikistan, Ukraine)</td>
<td>(Armenia, Azerbaijan, Belarus, Croatia, Montenegro, Moldova, Russia, Tajikistan)</td>
</tr>
<tr>
<td>Exposed healthcare, public safety, and emergency medical workers</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Other groups – please specify</td>
<td>(Kyrgyzstan, Moldova, Tajikistan)</td>
<td>(Kyrgyzstan, Moldova, Tajikistan)</td>
</tr>
</tbody>
</table>

HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus.
Data collected
Most responding countries (n=9) collected case-based demographic data such as patient identifier, address, sex, occupation, and time and place of birth and epidemiological data (Table 2). Among these, eight countries also collected laboratory results, and six clinical symptoms. Four countries collected data on the country in which infection was acquired, and two countries (Armenia and Moldova) on the ethnic identity of infected individuals. Six countries reported collecting or linking to information about human immunodeficiency virus (HIV) coinfection and HBV/HCV coinfection, while smaller numbers of countries reported doing so for liver transplant (n=3 for both diseases), liver cancer (n=4 for both diseases) and hepatitis-associated mortality (n=5 for both diseases).

Populations screened
All 10 countries reported screening blood and organ donors for both HBV and HCV (Table 3). All countries except the exception of Tajikistan reported screening pregnant women for HBV, and in six countries pregnant women were screened for HCV as well. Other populations screened in most countries included people living with HIV (n=8 for HBV; n=9 for HCV), haemodialysis patients (n=9 for HBV; n=8 for HCV), and exposed healthcare workers, emergency medical workers and public safety workers (n=10 for HBV; n=8 for HCV). Five countries reported screening PWID for both HBV and HCV. Only two countries reported screening inmates in closed settings (Croatia and Russia, for both diseases). One reported screening persons born in endemic areas (Moldova, for both HBV and HCV), and three, screening sexual contacts of infected persons (Armenia, Croatia and Russia, for both diseases). There were no countries in which sex workers or MSM were among the populations screened.

Discussion
This is the first survey that provides an overview of surveillance systems and screening programmes for viral hepatitis B and C in selected countries of the WHO European Region outside of the EU/EEA. Across the 10 countries that responded to our survey, common features of many national surveillance systems included mandatory surveillance, passive case-finding and the reporting of both acute and chronic HBV and HCV. The objectives of the surveillance systems were mostly similar among responding countries. There was considerable variation in the type and amount of data collected across countries; however, basic demographic, epidemiological and clinical data were reportedly collected in the majority of responding countries. Populations screened in most countries included blood and organ donors, pregnant women, people living with HIV, haemodialysis patients and people at risk of occupational exposure.

Similar to the ECDC’s 2009 survey of HBV and HCV surveillance in EU/EEA countries, we found that chronic disease surveillance lagged behind acute disease surveillance [12]. This is unsurprising since the traditional focus of surveillance has been newly identified symptomatic patients. When WHO last published guidance on HBV surveillance, in 2003, that document addressed only acute viral hepatitis [13]. The importance of tracking chronic HBV and HCV infections is now more widely recognised due to increased awareness of the burden of disease and to the impact of better treatments on the long-term health of people with chronic HBV and HCV. However, it appears that surveillance systems in some WHO European Region Member States are not reflective of this transition.

Confirming the stage of HBV and HCV infection is known to be challenging. There is no robust marker of acute HCV infection, and for both HBV and HCV, a combination of serological and molecular tests are often required [10]. These can be less accessible in resource-limited settings. The 2009 ECDC survey showed that some EU/EEA countries were not able to differentiate between acute and chronic cases [12], and this has remained an important problem in EU/EEA countries subsequent to the implementation of the ECDC’s regional surveillance programme, especially for HCV [14,15]. Our survey did not ask directly if countries are able to distinguish effectively between acute and chronic infections and did not collect information on the case definitions used. The fact that five of 10 responding countries stated that their surveillance systems include undefined hepatitis cases indirectly suggests that countries’ capacity to differentiate cases by disease stage may be limited and raises questions about the comparability and robustness of data across different WHO European Region Member States.

Case reporting is the core element of hepatitis surveillance, but it is known to provide a considerable underestimation of the true number of viral hepatitis cases [10]. Because viral hepatitis B and C infections are often asymptomatic, case reporting can be limited by testing practices and by lapses in the implementation of screening programmes. The hepatitis disease burden therefore can be assessed more accurately when case reporting is complemented by other sources of information including death registries, disease registries and serosurveys. Assessing the burden of disease from HBV and HCV is a highly complex undertaking. The most notable sequelae of chronic viral hepatitis – cirrhosis and liver cancer – are not exclusively attributable to HBV and HCV. At the same time, many people with HBV and HCV have comorbidities that might accelerate the development of complications of chronic infection [16,17]. The incorporation of data on conditions and outcomes associated with HBV and HCV into national surveillance allows for better assessment of the burden of disease and of temporal trends at the national level. However, the logistics of pooling data from multiple sources such as cancer registries, other disease registries and death certificate records is challenging even in countries with well-resourced...
健康系统。令人鼓舞的是，看到HBV和HCV surveillance in some of our study countries appears to encompass the gathering of information on key associated conditions and outcomes。在研究中，然而，研究结果表明，这些关联条件并没有在所有研究国家中得到充分记录。

尽管注射药物使用是驱动HBV和HCV epidemic in Europe [5]，欧洲国家中仅有一半的国家在研究中报告过针对PWID的筛查计划。2009年ECDC survey indicated that a number of EU/EEA countries also lacked targeted screening programmes for PWID [12]。在10个国家中，三个国家中，三个报告国家的高风险人群中，HBV和HCV screening efforts: inmates in closed settings, sex workers and MSM。HBV和HCV surveillance for the entire WHO European Region, which currently encompasses the 31 EU/EEA countries and 22 additional countries outside of the EU/EEA。我们的研究结果，通过提供一些国家针对HBV和HCV surveillance across national surveillance systems and provides a functioning regional viral hepatitis surveillance system that might perhaps be expanded through collaboration with other stakeholders。It is thus an opportune time to explore the prospect of instituting harmonised HBV and HCV surveillance for the entire WHO European Region, which currently encompasses the 31 EU/EEA countries and 22 additional countries outside of the EU/EEA。研究结果，通过提供一些国家针对HBV和HCV surveillance across national surveillance systems and provides a functioning regional viral hepatitis surveillance system that might perhaps be expanded through collaboration with other stakeholders。It is thus an opportune time to explore the prospect of instituting harmonised HBV and HCV surveillance for the entire WHO European Region, which currently encompasses the 31 EU/EEA countries and 22 additional countries outside of the EU/EEA。
need for additional research to illuminate key details about how surveillance is carried out in these and other European countries outside of the EU/EEA. The World Health Organization's first-ever global health sector strategy for viral hepatitis, adopted by the World Health Assembly on 28 May 2016, places viral hepatitis surveillance as one of the most important components of the strategic information framework, under the first of its five strategic directions: information for focused action [19]. It seems questionable whether progress under this strategy can be effectively measured in the WHO European Region without a cohesive effort to develop comprehensive and coordinated disease surveillance programmes in the Region. Our study, by providing a baseline overview of viral hepatitis surveillance and screening programmes in some European countries outside of the EU/EEA, contributes to the ECDC’s work in this area and informs future plans to harmonise and enhance strategic information activities in the entire WHO European Region.

*Erratum*

In the first sentence of the methods section, ‘Bulgaria’ was removed. This was corrected on 03 June 2016.

Conflict of interest

None declared.

Authors’ contributions

All authors contributed extensively to the work presented in this paper. IE conceived of the study, and led in its design and coordination. JVL and KSH prepared the initial analysis of the data and first draft of the article. JVL oversaw the writing process. AM reviewed and revised the draft with input from IE. All authors read and approved the final manuscript.

References


License and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.

This article is copyright of the authors, 2016.